Inhibikase Therapeutics (IKT)
NASDAQ:IKT
Recent Insider Trading Activity
Date | Name | Activity | Value |
|---|---|---|---|
Nov 24, 2025 | xxxxxxxxxxxxx | $2999999 |
Recent Hedge Fund Trading Activity
Date | Firm | Activity | Value |
|---|---|---|---|
Dec 31, 2025 | xxxxxxxxxxxxx | $12173465 | |
Dec 31, 2025 | xxxxxxxxxxxxx | $17681250 |
Top Shareholders
Holder | # of Shares | Type | % Holding | Value |
|---|---|---|---|---|
| 13,018,965 | Insider | 10.74% | 23,434,137 | |
| 8,625,000 | Institution | 7.11% | 15,525,000 | |
| 5,938,276 | Institution | 4.90% | 10,688,897 | |
| 5,421,568 | Institution | 4.47% | 9,758,822 | |
| 4,147,051 | Institution | 3.42% | 7,464,692 | |
| 3,797,533 | Institution | 3.13% | 6,835,559 | |
| 1,975,329 | Institution | 1.63% | 3,555,592 | |
| 1,460,000 | Insider | 1.20% | 2,628,000 | |
| 676,564 | Insider | 0.56% | 1,217,815 | |
| 670,661 | Institution | 0.55% | 1,207,190 |
Top Mutual Fund Holders
Holder | # of Shares | Type | % Holding | Value |
|---|---|---|---|---|
| 3,797,533 | Institution | 3.13% | 6,835,559 | |
| 670,661 | Institution | 0.55% | 1,207,190 | |
| 342,265 | Institution | 0.28% | 616,077 | |
| 317,048 | Institution | 0.26% | 570,686 | |
| 152,298 | Institution | 0.13% | 274,136 | |
| 78,659 | Institution | 0.06% | 141,586 | |
| 63,298 | Institution | 0.05% | 113,936 | |
| 56,270 | Institution | 0.05% | 101,286 | |
| 52,148 | Institution | 0.04% | 93,866 | |
| 40,000 | Institution | 0.03% | 72,000 |
Top ETF Holders
Holder | # of Shares | Type | % Holding | Value |
|---|---|---|---|---|
| 3,425,978 | Institution | 2.83% | 7,023,255 | |
| 1,290,269 | Institution | 1.06% | 2,322,484 | |
| 466,646 | Institution | 0.38% | 839,963 | |
| 371,555 | Institution | 0.31% | 761,688 | |
| 299,209 | Institution | 0.25% | 613,378 | |
| 155,207 | Institution | 0.13% | 279,373 | |
| 62,318 | Institution | 0.05% | 112,172 | |
| 40,275 | Institution | 0.03% | 82,564 | |
| 28,675 | Institution | 0.02% | 52,475 | |
| 6,410 | Institution | <0.01% | 13,141 |
FAQ
Who Owns Inhibikase Therapeutics (IKT)?
Currently, no data Available
What percentage of Inhibikase Therapeutics (IKT) stock is held by institutional investors?
Currently, no data Available
What percentage of Inhibikase Therapeutics (IKT) stock is held by retail investors?
Currently, no data Available
Who owns the most shares of Inhibikase Therapeutics (IKT)?
Sands Capital Life Sciences Pulse Fund II, L.P. owns the most shares of Inhibikase Therapeutics (IKT).
What is the significance of the ownership structure for a publicly traded company?
The ownership structure can impact the company's decision making, as large institutional investors may exert influence on the company's management and can also affect the company's stock price with their buying and selling patterns.